Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label trabectedin. Show all posts
Showing posts with label trabectedin. Show all posts
Friday, February 17, 2012

abstract: Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors (including OC)

›
Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors. Investigational new Drug...
Thursday, December 29, 2011

Medical News: ECCO-ESMO: Spikes in Liver Enzymes Common in Ovarian Cancer Tx (Trabectedin / Yondelis)

›
Action Points Note that this study was published as an abstract and presented at a conference. The...
Sunday, June 12, 2011

abstract: The activity of trabectedin (Yondelis)as a single agent or in combination with everolimus for clear cell carcinoma of the ovary

›
Note: in research (lab)
Wednesday, April 27, 2011

NICE Unable To Recommend Ovarian Cancer Drug In Final Guidance Due To Lack Of Appropriate Evidence (trabectedin (Yondelis)

›
Sunday, December 19, 2010

Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group

›
CONCLUSIONS: This combination was well tolerated and appears more active than the historical control of single agent taxane therapy in tho...
Sunday, October 03, 2010

full free access: New developments in treatment of ovarian carcinoma: focus on Trabectedin

›
Note : click on 'pdf' for full free access to paper
Tuesday, July 20, 2010

Trabectedin (Yondelis) plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval (full access)

›

Trabectedin (Yondelis) plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial — Ann Oncol (full free access)

›
Monday, June 28, 2010

repost: abstract: (Yondelis) Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer. BJ Monk et al

›
Note: Reposted from June 9th to coincide with Editorial from JCO; multinational study plus: JCO link
Friday, June 18, 2010

Regulator to reject ovarian cancer treatment approve Trabectedin (Yondelis)

›
18th June 2010 - The health regulator, "The National Institute for Health and Clinical Excellence (NICE), says a new treatment for ...
Thursday, June 03, 2010

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer. (multinational study)

›
Note : Trabectedin is also known as Yondelis PURPOSE The objective of this study was to compare the efficacy and safety of trabectedin plu...
Wednesday, May 26, 2010

Health Canada Approves Trabectedin for Relapsed Ovarian Cancer (Trabectedin//Yondelis)

›
May 26, 2010 — Health Canada has approved trabectedin ( Yondelis ; PharmaMar SA [Zeltia SA], marketed by Centocor Ortho Biotech Products, ...
Friday, April 23, 2010

PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention - yondelis/Trabectedin

›
Two trials provided new data on Yondelis(R) (trabectedin), a marine-based anti-tumor drug currently produced by chemical synthesis. Yondel...